Glura M XR 1000 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby improving glycemic control through increased insulin release and decreased glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by enhancing peripheral glucose uptake and utilization. The extended-release formulation of Glura M XR 1000 allows for once-daily dosing, promoting better patient compliance. This combination is particularly beneficial for patients inadequately controlled on metformin alone or those requiring dual therapy to achieve glycemic targets. Glura M XR 1000 should be used as an adjunct to diet and exercise and is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy.

Dosage & How to Use

Dosage information not available. Please consult your doctor or pharmacist.